Search citation statements
Paper Sections
Citation Types
Year Published
Publication Types
Relationship
Authors
Journals
Serum sickness: case reportA 39-year-old man developed serum sickness during treatment with rituximab for antiphospholipid syndrome (APS). The man, who presented to the hospital with flank and abdominal pain, had extensive thrombosis of the inferior vena cava. Antibeta-2-microglobulin and anticardiolipin antibodies confirmed the diagnosis of APS. He had undergone thrombectomy with partial recanalisation of inferior vena cava during hospitalisation. He was discharged on unspecified anticoagulants. Afterwards, he returned to the hospital with complaints of chest pain. Imaging studies confirmed the diagnosis of Budd-Chiari syndrome (BCS), which was further complicated by type 2 myocardial infarction, acute renal failure and ischaemic liver injury in the setting of catastrophic antiphospholipid syndrome (CAPS). He received plasmapheresis, azathioprine, immuneglobulin [IVIG], unspecified steroids and hydroxychloroquine with improvement in liver enzymes. He started receiving rituximab infusions [route and dosage not stated] to manage the increased antiphospholipid antibody titers during hospitalisation. Immediately, he developed rash, fevers and lymphadenopathy, which was consistent with rituximab-induced serum sickness [duration of treatment to reaction onset not stated].Rituximab was discontinued, and the therapy was switched to ocrelizumab and mycophenolic acid for management of the APS [ADR outcome not stated].
Serum sickness: case reportA 39-year-old man developed serum sickness during treatment with rituximab for antiphospholipid syndrome (APS). The man, who presented to the hospital with flank and abdominal pain, had extensive thrombosis of the inferior vena cava. Antibeta-2-microglobulin and anticardiolipin antibodies confirmed the diagnosis of APS. He had undergone thrombectomy with partial recanalisation of inferior vena cava during hospitalisation. He was discharged on unspecified anticoagulants. Afterwards, he returned to the hospital with complaints of chest pain. Imaging studies confirmed the diagnosis of Budd-Chiari syndrome (BCS), which was further complicated by type 2 myocardial infarction, acute renal failure and ischaemic liver injury in the setting of catastrophic antiphospholipid syndrome (CAPS). He received plasmapheresis, azathioprine, immuneglobulin [IVIG], unspecified steroids and hydroxychloroquine with improvement in liver enzymes. He started receiving rituximab infusions [route and dosage not stated] to manage the increased antiphospholipid antibody titers during hospitalisation. Immediately, he developed rash, fevers and lymphadenopathy, which was consistent with rituximab-induced serum sickness [duration of treatment to reaction onset not stated].Rituximab was discontinued, and the therapy was switched to ocrelizumab and mycophenolic acid for management of the APS [ADR outcome not stated].
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.